SCHEMBL608267

SCHEMBL608267

O=C(O)c1cc(NCCc2ccc(F)cc2C(F)(F)F)ccc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.52
STING1 Q86WV6 1/20 0.52
ALDH1A1 P00352 3/20 0.47
NOX4 Q9NPH5 2/20 0.47
MAPT P10636 2/20 0.47
RGS12 O14924 1/20 0.47
EGFR P00533 1/20 0.47
LCK P06239 1/20 0.47
CAMKK2 Q96RR4 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
KDM4C Q9H3R0 5/20 0.43
SYK P43405 2/20 0.42
P2RX1 P51575 1/20 0.41
TMPRSS4 Q9NRS4 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
MEN1 O00255 2/20 0.40
USP2 O75604 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391362 1.00 PPARA (0.52) PPARASTING1ALDH1A1NOX4MAPT
SCHEMBL4100274 0.91 PPARA (0.52) PPARASTING1ALDH1A1NOX4MAPT
SCHEMBL4093950 0.85 NOX4 (0.59) PPARASTING1ALDH1A1NOX4MAPT
SCHEMBL4101857 0.82 NOX4 (0.52) PPARASTING1ALDH1A1NOX4MAPT
SCHEMBL30473064 0.82 NOX4 (0.52) PPARASTING1ALDH1A1NOX4MAPT
SCHEMBL29388037 0.81 NOX4 (0.47) PPARASTING1ALDH1A1NOX4MAPT
SCHEMBL610770 0.81 NOX4 (0.47) PPARASTING1ALDH1A1NOX4MAPT
SCHEMBL4097800 0.79 PPARA (0.52) PPARASTING1ALDH1A1NOX4MAPT
SCHEMBL4095655 0.79 PPARA (0.52) PPARASTING1ALDH1A1NOX4MAPT
SCHEMBL27770274 0.76 EGFR (0.74) PPARASTING1ALDH1A1NOX4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3902536-B1 COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL GNT PHARMA CO LTD (KR) 2025-09-03 EP claimed
WO-2023156808-A2 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT PHARMA CO., LTD. (KR) 2023-08-24 WO claimed
US-20230233503-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT PHARMA CO., LTD. (KR) 2023-07-27 US claimed
US-20220249343-A1 COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF GNT PHARMA CO., LTD. (KR) 2022-08-11 US claimed
US-20220241231-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2022-08-04 US claimed
EP-3998058-A1 COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF GNT Pharma Co., Ltd (KR) 2022-05-18 EP claimed
CN-114096227-A Cosmetic compositions comprising 5-benzylaminosalicylic acid derivatives and methods of topical use thereof 吉恩特药业株式会社 2022-02-25 CN claimed
CN-113710242-A Compositions and methods for treating neurodegenerative disorders 吉恩特药业株式会社 2021-11-26 CN claimed
EP-3902536-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT Pharma Co., Ltd (KR) 2021-11-03 EP claimed
WO-2021006637-A1 COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF 주식회사 지엔티파마 2021-01-14 WO claimed
WO-2020136441-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2020-07-02 WO claimed
US-20200206172-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2020-07-02 US claimed
EP-2004164-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASES NEUROTECH PHARMACEUTICALS CO LTD (KR) 2018-08-08 EP claimed
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2013-11-28 US claimed
US-8455470-B2 Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases NEUROTECH PHARMACEUTICALS CO., LTD (KR) 2013-06-04 US claimed
US-20120040939-A1 MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2012-02-16 US claimed
CN-102316863-A The medical usage of 5-benzylamino salicyclic acid derivatives or its salt NEUROTECH PHARMACEUTICALS CO L 2012-01-11 CN claimed
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases GNT PHARMA CO., LTD. (KR) 2009-11-12 US claimed
EP-2004164-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES Neurotech Co., Ltd. (KR) 2008-12-24 EP claimed
WO-2007119973-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES NEUROTECH CO., LTD. (KR) 2007-10-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233503-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS HAO2, ACOX1, HAO1 PPARA 813/4885STING1 2942/4885ALDH1A1 309/4885
US-20220241231-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS PRNP, PSEN1, GRIK5 PPARA 3388/4885STING1 3242/4885ALDH1A1 859/4885
US-20120040939-A1 MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT HTR5A, HTR6, MC5R PPARA 1630/4885STING1 4235/4885ALDH1A1 133/4885
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B PPARA 223/4885STING1 3665/4885ALDH1A1 446/4885
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B PPARA 223/4885STING1 3665/4885ALDH1A1 446/4885
US-20220249343-A1 COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF ALOX5, ALOX15, IL5 PPARA 908/4885STING1 1303/4885ALDH1A1 93/4885
US-20200206172-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS PRNP, PSEN1, GRIK5 PPARA 3388/4885STING1 3242/4885ALDH1A1 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.